Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Nature
|
March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancer
Simon Bernatz, Vasco Prudente, Suraj Pai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer
Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer
B Ricciuti, S Scalera, X Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
JAMA Oncology
|
December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
Mehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Nature Communications
|
September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
Yoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
JTO Clinical and Research Reports
|
October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
Biagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Nature
|
March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancer
Simon Bernatz, Vasco Prudente, Suraj Pai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer
Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer
B Ricciuti, S Scalera, X Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
JAMA Oncology
|
December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
Mehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Nature Communications
|
September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
Yoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
JTO Clinical and Research Reports
|
October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
Biagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
Page
of 8